NASDAQ:FOLD Amicus Therapeutics Q3 2025 Earnings Results & Report Amicus Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 4, 2025. The company reported EPS of $0.17 versus the $0.12 consensus estimate, while revenue of $169.06 million topped the $165.24 million estimate by $3.83 million. Revenue increased 19.5% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 4, 2025TimeBefore Market OpensConference Call8:30 AM ET Amicus Therapeutics EPS ResultsActual EPS$0.17Consensus EPS $0.12Beat/MissBeat by +$0.05One Year Ago EPS$0.10EPS Beat Rate3 of last 8 quartersAmicus Therapeutics Revenue ResultsActual Revenue$169.06 millionExpected Revenue$165.24 millionBeat/MissBeat by +$3.83 millionYoY Revenue Growth+19.50%Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileConference Call Audio Live Call not available Earnings Conference CallAmicus Therapeutics Q3 202500:00 / 00:00Speed:1x1.25x1.5x2xSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsSlide DeckEarnings Release(8-K)Quarterly Report(10-Q) Amicus Therapeutics Q3 2025 Earnings FAQ Did Amicus Therapeutics beat earnings estimates for Q3 2025? Amicus Therapeutics (NASDAQ:FOLD) reported earnings of $0.17 per share for Q3 2025, beating the consensus estimate of $0.12. The report was announced on Tuesday, November 4, 2025. What was Amicus Therapeutics' revenue for Q3 2025? Amicus Therapeutics reported revenue of $169.06 million for Q3 2025, against a consensus estimate of $165.24 million. Where can I read Amicus Therapeutics' Q3 2025 earnings call transcript? The full Amicus Therapeutics Q3 2025 earnings conference call transcript is published on this page, including prepared remarks and the analyst Q&A session, along with the participants who spoke on the call. Amicus Therapeutics Earnings HeadlinesBitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacksAugust 20, 2026 | nypost.comNJohn Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 movesMay 15, 2026 | msn.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 11 at 1:00 AM | Profits Run (Ad)Amicus Gains Final Approval for BioMarin Acquisition CompletionApril 26, 2026 | theglobeandmail.comCIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)April 25, 2026 | fool.comAssessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total ReturnMarch 29, 2026 | finance.yahoo.comSee More Amicus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amicus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amicus Therapeutics and other key companies, straight to your email. Email Address About Amicus TherapeuticsAmicus Therapeutics (NASDAQ:FOLD) (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function. The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants. Beyond Fabry disease, Amicus is advancing a pipeline of investigational gene therapies and combination therapies, including programs targeting Pompe disease and Batten disease, with several candidates in late‐stage and mid‐stage clinical development. Founded in 2005 and headquartered in Cranbury, New Jersey, Amicus Therapeutics completed its initial public offering on the NASDAQ in 2015. The company maintains research and development operations in multiple locations across the United States and Europe, leveraging global manufacturing and regulatory expertise to support its clinical trials and commercial supply chain. Leadership at Amicus includes Chief Executive Officer Chirfi Guindo, who brings extensive experience in rare disease drug development, and John Crowley, co‐founder and Chairman of the Board. The company collaborates with leading pharmaceutical and academic partners to expand its platform and accelerate the development of novel therapies for underserved patient communities.View Amicus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
